Key result
Post-AVR GLP-1 receptor agonist use is linked to ~31% lower risk of composite adverse events.
Why the study?
Whether the cardiovascular benefits of GLP-1 receptor agonists extend to patients undergoing aortic valve replacement for severe aortic stenosis was unknown.
Does GLP-1 receptor agonist treatment reduce the composite of mortality, heart failure hospitalization, or aortic valve reoperation in patients with severe aortic stenosis undergoing aortic valve replacement?
Cohort (n=292)
Yes
Does GLP-1 receptor agonist treatment reduce the composite of mortality, heart failure hospitalization, or aortic valve reoperation in patients with severe aortic stenosis undergoing aortic valve replacement?
Hazard Ratio: 0.69 (95% CI 0.5–0.96)
p-value: p=0.029
Treatment with GLP-1 receptor agonists is associated with a reduced risk of a composite of mortality, heart failure hospitalization, and aortic valve reoperation in patients who have undergone aortic valve replacement for severe aortic stenosis.
Should not yet change post-AVR practice; leaves open a potential role for GLP-1 agonists pending randomized confirmation.
Background GLP-1 receptor agonists reduce major adverse cardiovascular events among patients with diabetes, overweight, and obesity. Whether these benefits extend to patients undergoing aortic valve replacement (AVR) for severe aortic stenosis (AS) remains unknown. Thus, we investigated the association between GLP-1 receptor agonist treatment and cardiovascular outcomes after AVR. Methods Nationwide population-based cohort study including consecutive patients with severe AS undergoing TAVI or SAVR in Western Denmark between January, 2016 and April, 2022. Patients were followed until death, emigration, crossover, or end of follow up on May 12, 2026. Propensity score-matching was performed to balance confounding. The primary outcome was a composite of all-cause mortality, heart failure hospitalization, or aortic valve reoperation. Secondary outcomes included all-cause mortality, heart failure hospitalization, aortic valve reoperation, with analyses accounting for the competing risk of death. Results Among 5259 eligible patients undergoing AVR, 292 propensity score-matched patients were included in the final analyses. During a mean follow up of 4.8±2.4 years, GLP-1 receptor agonist treatment was associated with a lower risk of the primary composite outcome compared with controls (HR 0.69, 95%CI 0.50-0.96, p=0.029). GLP-1 receptor agonist treatment was also associated with lower risk of all-cause mortality (HR 0.66, 95%CI 0.46-0.95, p=0.025). In competing risk analyses accounting for death, lower risks were observed for heart failure hospitalization (HR 0.67, 95%CI 0.48-0.93, p=0.018), and aortic valve reoperation (HR 0.69, 95%CI 0.49-0.98, p=0.037). Conclusion Treatment with GLP-1 receptor agonists was associated with lower risk of cardiovascular outcomes including mortality following AVR among patients with severe AS.
No takes yet. Share an insight, caveat, or question.
Krasniqi et al. (2026) conducted a cohort in Severe aortic stenosis (n=292). GLP-1 receptor agonists vs. Controls was evaluated on Composite of all-cause mortality, heart failure hospitalization, or aortic valve reoperation (HR 0.69, 95% CI 0.50-0.96, p=0.029). GLP-1 receptor agonist treatment following aortic valve replacement was associated with a lower risk of mortality, heart failure hospitalization, or reoperation (HR 0.69; 95% CI 0.50-0.96; p=0.029).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: